Citations

Clear

4847 citation(s) found for "Tu, Eric".

Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes
Collaborative, The Beyond TME, Antoniou, Anthony , Beynon, John, Bhangu, Aneel , Bose, Pradeep, Boyle, Kirsten, Branagan, Graham , Burling, David , Chang, George J. , Clark, Susan K. , Colquhoun, Patrick, Crane, Christopher H. , Darzi, Ara , Das, Prajnan , Delaney, Conor P. , Desai, Anant, Davies, Mark, Dozois, Eric J. , Fitzgerald, J.E.F. , Frizelle, Frank , George, Bruce , George, Mark, Georgiou, Panagiotis , Gupta, Arun , Harris, Dean , Hawkins, M. , Holm, Torbjörn, Hompes, Roel , Jeys, Lee , Jenkins, John T. , Kiran, Ravi P. , Koh, Cherry , Laurberg, Søren , Law, Wai Lun, Liberman, A. Sender , McArthur, D. Ray, Mirnezami, Alex H. , Moran, Brendan , Mortenson, Neil, Myers, Eddie, Nicholls, R. John, O’Connell, P. R. , O’Dwyer, Sarah , Oliver, Alex, Pallan, Arvind, Patel, Prashant , Patel, Uday , Radley, Simon, Ramsey, Kelvin , Rasmussen, P., Richard, Carole, Rutten, H.J.T. , Sagar, P. M. , Sebag‐Montefiore, David , Stocchi, Luca , Swallow, Carol J. , Tait, Diana , Tan, Emile , Tekkis, Paris, As, Nicholas van , Vuong, T. , Wiggers, Theo , Wilson, Malcolm , Winter, Desmond C. , Woodhouse, Christopher, Collaborative, The Beyond TME, Ali, Simak , Brown, Gina , Wilt, Johannes H.W. de , Desai, Anant , Dietz, David , Duff, Michael J. B. , Dziki, Adam Janusz , Glynne‐Jones, Rob , Goldin, Robert , Harji, Deena Pravin , Heriot, Alexander G. , Marshall, Michelle Berger , Radley, Simon, Solomon, Michael J. , Jeys, Lee M

Mayo Clinic

British Journal of Surgery | June 21, 2013 | Volume: 100 | Issue: 8 | Pages: E1-E33

10.1002/bjs.9192_1 | PMID 23901427 Get It

Consensus abstract Background The management of primary rectal cancer beyond total mesorectal excision planes (PRC-bTME) and recurrent rectal cancer (RRC) is challenging. There is global variation in standards and no guidelines exist. To achieve cure most patients require extended, multivisceral, exenterative surgery, beyond conventional total mesorectal excision planes. The aim of the Beyond TME Group was to achieve consensus on the definitions and principles of management, and to identify areas of research priority. Methods Delphi methodology was used to achieve consensus. The Group consisted of invited experts from surgery, radiology, oncology and pathology. The process included two international dedicated discussion conferences, formal feedback, three rounds of editing and two rounds of anonymized web-based voting. Consensus was achieved with more than 80 per cent agreement; less than 80 per cent agreement indicated low consensus. During conferences held in September 2011 and March 2012, open discussion took place on areas in which there is a low level of consensus. Results The final consensus document included 51 voted statements, making recommendations on ten key areas of PRC-bTME and RRC. Consensus agreement was achieved on the recommendations of 49 statements, with 34 achieving consensus in over 95 per cent. The lowest level of consensus obtained was 76 per cent. There was clear identification of the need for referral to a specialist multidisciplinary team for diagnosis, assessment and further management. Conclusion The consensus process has provided guidance for the management of patients with PRC-bTME or RRC, taking into account global variations in surgical techniques and technology. It has further identified areas of research priority.
Risks and Benefits of Anticoagulation in Atrial Fibrillation
Cullen, Michael W. , Kim, Sunghee , Piccini, Jonathan P. , Ansell, Jack , Fonarow, Gregg C. , Hylek, Elaine M. , Singer, Daniel E. , Mahaffey, Kenneth W. , Kowey, Peter R. , Thomas, Laine , Go, Alan S. , Chang, Paul, Lópes, Renato D. , Peterson, Eric D. , Gersh, Bernard J.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | June 12, 2013 | Volume: 6 | Issue: 4 | Pages: 461-469

10.1161/circoutcomes.113.000127 | PMID 23759473 Get It

Background— Patients with atrial fibrillation (AF) at the highest stroke risk derive the largest benefit from oral anticoagulation (OAC). Those with the highest stroke risk have been paradoxically less likely to receive OAC. This study assessed the association between stroke and bleeding risk on rates of OAC. Methods and Results— We analyzed OAC use among 10 098 patients with AF from 174 community-based outpatient practices enrolled in 2010–2011 in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). OAC was defined as warfarin or dabigatran use at study enrollment. Stroke and bleeding risk were calculated using congestive heart failure, hypertension, age, diabetes mellitus, prior stroke (CHADS 2 ), and anticoagulation and risk factors in AF (ATRIA) scores, respectively. The mean subject age was 73 years; 58% were men. Overall, 76% of patients received OAC (71% warfarin and 5% dabigatran). The use of OAC increased among those with higher CHADS 2 scores, from 53% for CHADS 2 =0 to 80% for CHADS 2 ≥2 ( P <0.001). OAC use fell slightly with increasing ATRIA bleeding risk score, from 81% for ATRIA=3 to 73% for ATRIA≥5 ( P <0.001). A significant interaction existed between ATRIA and CHADS 2 scores ( P =0.021). Among those with low bleeding risk, use of OAC increased significantly with increasing stroke risk. Among those with high bleeding risk, CHADS 2 stroke risk had a smaller impact on use of OAC. Conclusions— In community-based outpatients with AF, use of OAC was high and driven by not only predominantly stroke but also bleeding risk. Stroke risk significantly affects OAC use among those with low bleeding risk, whereas those with high bleeding risk demonstrate consistently lower use of OAC regardless of stroke risk.
Genomic Association Analysis of Common Variants Influencing Antihypertensive Response to Hydrochlorothiazide
Boerwinkle, Eric , O’Connell, Jeffrey R. , Bailey, Kent R. , Chapman, Arlene B. , McDonough, Caitrin W. , Beitelshees, Amber L. , Schwartz, Gary L. , Gums, John G. , Padmanabhan, Sandosh , Hiltunen, Timo P. , Citterio, Lorena , Donner, Kati , Hedner, Thomas, Lanzani, Chiara , Melander, Olle , Saarela, Janna , Wahlstrand, Björn, Manunta, Paolo , Kontula, Kimmo , Dominiczak, Anna F. , Johnson, Julie A. , Beitelshees, Amber L. , Turner, Stephen T. , Gong, Yan , Chapman, Arlene B. , Ripatti, Samuli , Cooper‐DeHoff, Rhonda M. , Padmanabhan, Sandosh , Dominiczak, Anna F.

Mayo Clinic

Hypertension | June 11, 2013 | Volume: 62 | Issue: 2 | Pages: 391-397

10.1161/hypertensionaha.111.00436 | PMID 23753411 Get It

To identify novel genes influencing blood pressure response to thiazide diuretic therapy for hypertension, we conducted genome-wide association meta-analyses of ≈1.1 million single-nucleotide polymorphisms in a combined sample of 424 European Americans with primary hypertension treated with hydrochlorothiazide from the Pharmacogenomic Evaluation of Antihypertensive Responses study (n=228) and the Genetic Epidemiology of Responses to Antihypertensive study (n=196). Polymorphisms associated with blood pressure response at P <10 –5 were tested for replication of the associations in independent samples of hydrochlorothiazide-treated European hypertensives. The rs16960228 polymorphism in protein kinase C, α replicated for same-direction association with diastolic blood pressure response in the Nordic Diltiazem study (n=420) and the Genetics of Drug Responsiveness in Essential Hypertension study (n=206), and the combined 4-study meta-analysis P value achieved genome-wide significance ( P =3.3×10 −8 ). Systolic or diastolic blood pressure responses were consistently greater in carriers of the rs16960228 A allele than in GG homozygotes (>4/4 mm Hg) across study samples. The rs2273359 polymorphism in the GNAS-EDN3 region also replicated for same-direction association with systolic blood pressure response in the Nordic Diltiazem study, and the combined 3-study meta-analysis P value approached genome-wide significance ( P =5.5×10 −8 ). The findings document clinically important effects of genetic variation at novel loci on blood pressure response to a thiazide diuretic, which may be a basis for individualization of antihypertensive drug therapy and identification of new drug targets.
Vascular Access Site Injury After Transfemoral Transcatheter Aortic Valve Insertion
Greason, Kevin L. , Suri, Rakesh M. , Huebner, Marianne , Reeder, Guy S., Williamson, Eric E. , Rihal, Charanjit S. , Mathew, Verghese, Nkomo, Vuyisile T. , Rihal, Charanjit S.

Mayo Clinic

Journal of Cardiac Surgery | June 11, 2013 | Volume: 28 | Issue: 4 | Pages: 348-352

10.1111/jocs.12140 | PMID 23750934 Get It

Posttranscriptional Regulation of PER1 Underlies the Oncogenic Function of IREα
Pluquet, Olivier , Dejeans, Nicolas, Bouchecareilh, Marion , Lhomond, Stéphanie , Pineau, Raphaël , Higa, Arisa, Delugin, Maylis, Combe, Chantal, Loriot, Sandrine, Cubel, Gaëlle, Dugot‐Senant, Nathalie, Vital, Anne, Loiseau, Hugues , Gosline, Sara J.C. , Taouji, Saı̈d , Hallett, Michael , Anderson, Keith, Rosenbaum, Jean , Saltel, Frédéric , Fernández-Zapico, Martín E. , Chevet, Éric , Loriot, Sandrine, Sarkaria, Jann N. , Wu, Wenting , Rodríguez, Fausto J. , Chevet, Eric

Mayo Clinic

Cancer Research | June 11, 2013 | Volume: 73 | Issue: 15 | Pages: 4732-4743

10.1158/0008-5472.can-12-3989 | PMID 23752693 Get It

Abstract Growing evidence supports a role for the unfolded protein response (UPR) in carcinogenesis; however, the precise molecular mechanisms underlying this phenomenon remain elusive. Herein, we identified the circadian clock PER1 mRNA as a novel substrate of the endoribonuclease activity of the UPR sensor IRE1α. Analysis of the mechanism shows that IRE1α endoribonuclease activity decreased PER1 mRNA in tumor cells without affecting PER1 gene transcription. Inhibition of IRE1α signaling using either siRNA-mediated silencing or a dominant-negative strategy prevented PER1 mRNA decay, reduced tumorigenesis, and increased survival, features that were reversed upon PER1 silencing. Clinically, patients showing reduced survival have lower levels of PER1 mRNA expression and increased splicing of XBP1, a known IRE-α substrate, thereby pointing toward an increased IRE1α activity in these patients. Hence, we describe a novel mechanism connecting the UPR and circadian clock components in tumor cells, thereby highlighting the importance of this interplay in tumor development. Cancer Res; 73(15); 4732–43. ©2013 AACR.
Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes
Collaborative, The Beyond TME, Antoniou, Anthony , Beynon, John, Bose, Pradeep, Boyle, Kirsten, Branagan, Graham , Brown, Gina , Burling, David , Chang, George J. , Clark, Susan K. , Colquhoun, Patrick, Crane, Christopher H. , Darzi, Ara , Das, Prajnan , Wilt, Johannes H. W. de, Delaney, Conor P. , Desai, Anant, Davies, Mark, Dozois, Eric J. , Fitzgerald, J.E.F. , Frizelle, Frank , George, Bruce , George, Mark, Georgiou, Panagiotis , Glynne‐Jones, R., Goldin, Robert , Gupta, Arun , Harris, Dean , Hawkins, M. , Holm, Torbjörn, Jenkins, John T. , Kiran, Ravi P. , Laurberg, Søren , Law, Wai Lun, Liberman, A. Sender , McArthur, D. Ray, Mirnezami, Alex H. , Moran, Brendan , Mortenson, Neil, Myers, Eddie, Nicholls, R. John, O’Connell, P. R. , O’Dwyer, Sarah , Oliver, Alex, Pallan, Arvind, Patel, Prashant , Radley, Simon, Ramsey, Kelvin , Rasmussen, P., Richard, Carole, Rutten, H.J.T. , Sagar, P. M. , Sebag‐Montefiore, David , Solomon, Michael J. , Stocchi, Luca , Swallow, Carol J. , Tait, Diana , Tekkis, Paris, As, Nicholas van , Vuong, T. , Wiggers, Theo , Wilson, Malcolm , Winter, Desmond C. , Woodhouse, Christopher, Coombes, R. Charles , Collaborative, The Beyond TME, Ali, Simak , Bhangu, Aneel , Desai, Anant , Dietz, David , Duff, Michael J. B. , Dziki, Adam Janusz , Harji, Deena Pravin , Heriot, Alexander G. , Hompes, Roel , Jeys, Lee , Koh, Cherry , Marshall, Michelle Berger , Patel, Uday , Radley, Simon, Tan, Emile , Solomon, Michael J

Mayo Clinic

British Journal of Surgery | June 10, 2013 | Volume: 100 | Issue: 8 | Pages: 1009-1014

10.1002/bjs.9192 | PMID 23754654 Get It

Consensus abstract Background The management of primary rectal cancer beyond total mesorectal excision planes (PRC-bTME) and recurrent rectal cancer (RRC) is challenging. There is global variation in standards and no guidelines exist. To achieve cure most patients require extended, multivisceral, exenterative surgery, beyond conventional total mesorectal excision planes. The aim of the Beyond TME Group was to achieve consensus on the definitions and principles of management, and to identify areas of research priority. Methods Delphi methodology was used to achieve consensus. The Group consisted of invited experts from surgery, radiology, oncology and pathology. The process included two international dedicated discussion conferences, formal feedback, three rounds of editing and two rounds of anonymized web-based voting. Consensus was achieved with more than 80 per cent agreement; less than 80 per cent agreement indicated low consensus. During conferences held in September 2011 and March 2012, open discussion took place on areas in which there is a low level of consensus. Results The final consensus document included 51 voted statements, making recommendations on ten key areas of PRC-bTME and RRC. Consensus agreement was achieved on the recommendations of 49 statements, with 34 achieving consensus in over 95 per cent. The lowest level of consensus obtained was 76 per cent. There was clear identification of the need for referral to a specialist multidisciplinary team for diagnosis, assessment and further management. Conclusion The consensus process has provided guidance for the management of patients with PRC-bTME or RRC, taking into account global variations in surgical techniques and technology. It has further identified areas of research priority.
Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2
Lam, Erek M., Shepard, Paul W., Louis, Erik K. St. , Dueffert, Lucas G., Slocumb, Nancy L., McCarter, Stuart J. , Silber, Michael H. , Olson, Eric J. , Milone, Margherita , Boeve, Bradley F. , Somers, Virend K. , St Louis, E K , McCarter, Stuart J

Mayo Clinic

Neurology | June 8, 2013 | Volume: 81 | Issue: 2 | Pages: 157-164

10.1212/wnl.0b013e31829a340f | PMID 23749798 Get It

Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology
Whitwell, Jennifer L. , Parisi, Joseph E., Gunter, Jeffrey L. , Weigand, Stephen D. , Ahlskog, J. Eric , Petersen, Ronald C. , Dickson, Dennis W. , Josephs, Keith A. , Jack, Clifford R. , Boeve, Bradley F. , Dickson, Dennis W

Mayo Clinic

European Journal of Neurology | June 7, 2013 | Volume: 20 | Issue: 10 | Pages: 1417-1422

10.1111/ene.12212 | PMID 23746093 Get It

Background and purposeMidbrain atrophy is a characteristic feature of progressive supranuclear palsy (PSP), although it is unclear whether it is associated with the PSP syndrome (PSPS) or PSP pathology. The aim of the present study was to determine whether midbrain atrophy is a useful biomarker of PSP pathology, or whether it is only associated with typical PSPS.MethodsAll autopsy‐confirmed subjects were identified with the PSP clinical phenotype (i.e. PSPS) or PSP pathology and a volumetric MRI. Of 24 subjects with PSP pathology, 11 had a clinical diagnosis of PSPS (PSP‐PSPS), and 13 had a non‐PSPS clinical diagnosis (PSP‐other). Three subjects had PSPS and corticobasal degeneration pathology (CBD‐PSPS). Healthy control and disease control groups (i.e. a group without PSPS or PSP pathology) and a group with CBD pathology and corticobasal syndrome (CBD‐CBS) were selected. The midbrain area was measured in all subjects. [Correction added on 21 June 2013, after first online publication: the abbreviation of corticobasal degeneration pathology was changed from CBD‐PSP to CBD‐PSPS.]ResultsThe midbrain area was reduced in each group with clinical PSPS (with and without PSP pathology). The group with PSP pathology and non‐PSPS clinical syndromes did not show reduced midbrain area. Midbrain area was smaller in the subjects with PSPS than in those without PSPS (P < 0.0001), with an area under the receiver operator curve of 0.99 (0.88, 0.99). A midbrain area cut‐point of 92 mm2 provided optimum sensitivity (93%) and specificity (89%) for differentiation.ConclusionMidbrain atrophy is associated with the clinical presentation of PSPS, but not with the pathological diagnosis of PSP in the absence of clinical PSPS. This finding has important implications for the utility of midbrain measurements as diagnostic biomarkers for PSP pathology.
Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database
McCleary, Nadine J. , Meyerhardt, Jeffrey A. , Green, Erin , Yothers, Greg , Gramont, Aimery de , Twelves, Christopher , Saltz, Leonard B. , Haller, Daniel G. , Sargent, Daniel J. , Cutsem, Eric Van , O’Connell, Michael J. , Sargent, Daniel J , Saltz, Leonard , Meyerhardt, Jeffrey A , Yothers, Greg

Mayo Clinic

Journal of Clinical Oncology | June 4, 2013 | Volume: 31 | Issue: 20 | Pages: 2600-2606

10.1200/jco.2013.49.6638 | PMID 23733765 Get It

Purpose Prior studies have suggested that patients with stage II/III colon cancer receive similar benefit from intravenous (IV) fluoropyrimidine adjuvant therapy regardless of age. Combination regimens and oral fluorouracil (FU) therapy are now standard. We examined the impact of age on colon cancer recurrence and mortality after adjuvant therapy with these newer options. Patients and Methods We analyzed 11,953 patients age < 70 and 2,575 age ≥ 70 years from seven adjuvant therapy trials comparing IV FU with oral fluoropyrimidines (capecitabine, uracil, or tegafur) or combinations of fluoropyrimidines with oxaliplatin or irinotecan in stage II/III colon cancer. End points were disease-free survival (DFS), overall survival (OS), and time to recurrence (TTR). Results In three studies comparing oxaliplatin-based chemotherapy with IV FU, statistically significant interactions were not observed between treatment arm and age (P interaction = .09 for DFS, .05 for OS, and .36 for TTR), although the stratified point estimates suggested limited benefit from the addition of oxaliplatin in elderly patients (DFS hazard ratio [HR], 0.94; 95% CI, 0.78 to 1.13; OS HR, 1.04; 95% CI, 0.85 to 1.27). No significant interactions by age were detected with oral fluoropyrimidine therapy compared with IV FU; noninferiority was supported in both age populations. Conclusion Patients age ≥ 70 years seemed to experience reduced benefit from adding oxaliplatin to fluoropyrimidines in the adjuvant setting, although statistically, there was not a significant effect modification by age, whereas oral fluoropyrimidines retained their efficacy.